Ivantis Completes PMA Submission for Hydrus Microstent

November 3, 2017: By Jon Swedien
Ivantis Hydrus

Ivantis Hydrus

Ivantis has submitted to the US FDA its final premarket approval (PMA) module for the Hydrus Microstent as a treatment for open-angle glaucoma, the Irvine, California, company announced Oct. 31.

The Hydrus is a minimally invasive glaucoma surgery (MIGS) device designed to reduce intraocular pressure (IOP). Roughly the size of an eyelash, the device opens a bypass through the trabecular meshwork and then dilates and scaffolds Schlemm’s canal to enhance outflow.

The submission is based on the HORIZON pivotal trial, a 556 patient, prospective, randomized trial conducted at 38 centers in nine countries. Study subjects with mild to moderate primary open-angle glaucoma were randomized to receive cataract surgery alone or cataract surgery plus the Hydrus. Subjects were followed for two years. The HORIZON Study is the largest MIGS randomized controlled trial completed to date and the first pivotal trial to span the globe, Ivantis said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022